SCHEMBL1794036

SCHEMBL1794036

CCN(CC)C/C=C/CNCc1ccc(C(=O)N(Cc2ncc[nH]2)Cc2ncc[nH]2)cc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 4/20 0.64
TAAR1 Q96RJ0 1/20 0.37
CTSD P07339 1/20 0.34
OPRD1 P41143 3/20 0.34
OPRM1 P35372 2/20 0.34
OPRK1 P41145 1/20 0.34
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
CYP2D6 P10635 1/20 0.33
TSHR P16473 1/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1794040 1.00 CXCR4 (0.64) CXCR4TAAR1CTSDOPRD1OPRM1
SCHEMBL1793371 0.81 CXCR4 (0.78) CXCR4CTSDHDAC1HDAC6NPC1
SCHEMBL1793967 0.81 CXCR4 (0.86) CXCR4CTSDHDAC1HDAC6NPC1
SCHEMBL1795822 0.79 CXCR4 (0.87) CXCR4
SCHEMBL1797198 0.79 CXCR4 (0.94) CXCR4
SCHEMBL2693644 0.79 CXCR4 (0.74) CXCR4CTSDHDAC1HDAC6NPC1
SCHEMBL1793193 0.78 CXCR4 (1.00) CXCR4
SCHEMBL1792747 0.77 CXCR4 (0.98) CXCR4
SCHEMBL1793290 0.77 CXCR4 (0.70) CXCR4CTSDOPRD1OPRM1OPRK1
SCHEMBL1792401 0.75 CXCR4 (0.54) CXCR4TAAR1OPRD1OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822459-B2 Compound containing basic group and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-09-02 US disclosed
US-20110142856-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2011-06-16 US disclosed
US-7951816-B2 Compound containing basic group and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2011-05-31 US disclosed
US-20080009495-A1 Compound Containing Basic Group and Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2008-01-10 US disclosed
EP-1790639-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110142856-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF CXCR4, CCR5, CXCL12 CXCR4 1/4885TAAR1 903/4885CTSD 3749/4885
US-20080009495-A1 Compound Containing Basic Group and Use Thereof CXCR4, CCR5, CXCR3 CXCR4 1/4885TAAR1 1001/4885CTSD 3690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.